Log In
BCIQ
Print this Print this
 

tildrakizumab (MK-3222) (formerly SCH 900222)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionAnti-IL-23 antibody
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionInterleukin-23 (IL-23) inhibitor
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe chronic plaque psoriasis
Regulatory Designation
PartnerAlmirall S.A.;
Sun Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$130.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/27/2016

Undisclosed

$50.0M

Undisclosed

09/17/2014

Undisclosed

$80.0M

Undisclosed

Get a free BioCentury trial today